Skip to main content
Erschienen in: Supportive Care in Cancer 12/2021

06.07.2021 | Original Article

Risk factor analysis for taxane-associated acute pain syndrome under the dexamethasone prophylaxis

verfasst von: Yoshitaka Saito, Yoh Takekuma, Masaki Kobayashi, Tatsuhiko Sakamoto, Hiroko Yamashita, Mitsuru Sugawara

Erschienen in: Supportive Care in Cancer | Ausgabe 12/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Taxane-associated acute pain syndrome (T-APS) reportedly occurs in approximately 70% of patients undergoing therapy. We have previously reported that additional dexamethasone (DEX) administration attenuates T-APS. The aim of this study was to reveal risk factor(s) associated with the incidence of T-APS under prophylactic DEX administration.

Methods

In total, 143 patients with breast cancer who received docetaxel (75 mg/m2) or paclitaxel (175 mg/m2)-containing treatment regimens were enrolled. DEX (4–8 mg) was orally administered on days 2–4. Risk factors for the incidence of ≥ G2 and all-grade T-APS, as well as T-APS incidence between taxane-containing regimens in the first cycle, were retrospectively evaluated.

Results

Approximately 90% of the patients received taxanes for adjuvant or neoadjuvant chemotherapy. Overall, 55% of patients administered 4 mg DEX, whereas 45% received 8 mg DEX. Pegfilgrastim was administered in 27% of patients. Incidence of ≥ G2 and all-grade T-APS was 23.8%, and 69.2%, respectively. Univariate and multivariate analyses revealed that administration of pegfilgrastim is an independent risk factor for the incidence of ≥ G2 and all-grade T-APS; age younger than 55 years is also a risk factor for all-grade T-APS. Moreover, the incidence of ≥ G2 and all-grade T-APS was 45.5% and 81.8% in a paclitaxel regimen, and 22.0% and 68.2% in docetaxel-including regimens, respectively, revealing increased tendency with paclitaxel administration, with no significant differences.

Conclusion

Pegfilgrastim co-administration is an independent risk factor for ≥ G2 and all-grade T-APS, and age younger than 55 years is a risk factor of all-grade T-APS under prophylactic DEX administration.
Literatur
1.
Zurück zum Zitat Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M et al (2012) Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379:432–444CrossRef Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M et al (2012) Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379:432–444CrossRef
2.
Zurück zum Zitat De Laurentiis M, Cancello G, D’Agostino D, Giuliano M, Giordano A, Montagna E et al (2008) Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol 26:44–53PubMedCrossRef De Laurentiis M, Cancello G, D’Agostino D, Giuliano M, Giordano A, Montagna E et al (2008) Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol 26:44–53PubMedCrossRef
3.
Zurück zum Zitat Kramer JA, Curran D, Piccart M, de Haes JC, Bruning PF, Klijn JG et al (2000) Randomised trial of paclitaxel versus doxorubicin as first-line chemotherapy for advanced breast cancer: quality of life evaluation using the EORTC QLQ-C30 and the Rotterdam symptom checklist. Eur J Cancer 36:1488–1497PubMedCrossRef Kramer JA, Curran D, Piccart M, de Haes JC, Bruning PF, Klijn JG et al (2000) Randomised trial of paclitaxel versus doxorubicin as first-line chemotherapy for advanced breast cancer: quality of life evaluation using the EORTC QLQ-C30 and the Rotterdam symptom checklist. Eur J Cancer 36:1488–1497PubMedCrossRef
4.
Zurück zum Zitat Katsumata N, Watanabe T, Minami H, Aogi K, Tabei T, Sano M et al (2009) Phase III trial of doxorubicin plus cyclophosphamide (AC), docetaxel, and alternating AC and docetaxel as front-line chemotherapy for metastatic breast cancer: Japan Clinical Oncology Group trial (JCOG9802). Ann Oncol 20:1210–1215PubMedCrossRef Katsumata N, Watanabe T, Minami H, Aogi K, Tabei T, Sano M et al (2009) Phase III trial of doxorubicin plus cyclophosphamide (AC), docetaxel, and alternating AC and docetaxel as front-line chemotherapy for metastatic breast cancer: Japan Clinical Oncology Group trial (JCOG9802). Ann Oncol 20:1210–1215PubMedCrossRef
5.
Zurück zum Zitat Sledge GW, Neuberg D, Bernardo P, Ingle JN, Martino S, Rowinsky EK et al (2003) Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 21:588–592PubMedCrossRef Sledge GW, Neuberg D, Bernardo P, Ingle JN, Martino S, Rowinsky EK et al (2003) Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 21:588–592PubMedCrossRef
6.
Zurück zum Zitat Megerdichian C, Olimpiadi Y, Hurvitz SA (2014) nab-Paclitaxel in combination with biologically targeted agents for early and metastatic breast cancer. Cancer Treat Rev 40:614–625PubMedCrossRef Megerdichian C, Olimpiadi Y, Hurvitz SA (2014) nab-Paclitaxel in combination with biologically targeted agents for early and metastatic breast cancer. Cancer Treat Rev 40:614–625PubMedCrossRef
7.
Zurück zum Zitat Saito Y, Kobayashi M, Yamada T, Sakakibara-Konishi J, Shinagawa N, Kinoshita I et al (2020) Efficacy of additional dexamethasone administration for the attenuation of paclitaxel-associated acute pain syndrome. Support Care Cancer 28:221–227PubMedCrossRef Saito Y, Kobayashi M, Yamada T, Sakakibara-Konishi J, Shinagawa N, Kinoshita I et al (2020) Efficacy of additional dexamethasone administration for the attenuation of paclitaxel-associated acute pain syndrome. Support Care Cancer 28:221–227PubMedCrossRef
8.
Zurück zum Zitat Chiu N, Zhang L, Dent R, Giotis A, van Draanen J, Gallo-Hershberg D et al (2018) A prospective study of docetaxel-associated pain syndrome. Support Care Cancer 26:203–211PubMedCrossRef Chiu N, Zhang L, Dent R, Giotis A, van Draanen J, Gallo-Hershberg D et al (2018) A prospective study of docetaxel-associated pain syndrome. Support Care Cancer 26:203–211PubMedCrossRef
9.
Zurück zum Zitat Fernandes R, Mazzarello S, Majeed H, Smith S, Shorr R, Hutton B et al (2016) Treatment of taxane acute pain syndrome (TAPS) in cancer patients receiving taxane-based chemotherapy-a systematic review. Support Care Cancer 24:1583–1594PubMedCrossRef Fernandes R, Mazzarello S, Majeed H, Smith S, Shorr R, Hutton B et al (2016) Treatment of taxane acute pain syndrome (TAPS) in cancer patients receiving taxane-based chemotherapy-a systematic review. Support Care Cancer 24:1583–1594PubMedCrossRef
10.
Zurück zum Zitat Fernandes R, Mazzarello S, Hutton B, Shorr R, Majeed H, Ibrahim MF et al (2016) Taxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy for breast cancer-a systematic review. Support Care Cancer 24:3633–3650PubMedCrossRef Fernandes R, Mazzarello S, Hutton B, Shorr R, Majeed H, Ibrahim MF et al (2016) Taxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy for breast cancer-a systematic review. Support Care Cancer 24:3633–3650PubMedCrossRef
11.
Zurück zum Zitat Kunitoh H, Saijo N, Furuse K, Noda K, Ogawa M (1998) Neuromuscular toxicities of paclitaxel 210 mg m(-2) by 3-hour infusion. Br J Cancer 77:1686–1688PubMedPubMedCentralCrossRef Kunitoh H, Saijo N, Furuse K, Noda K, Ogawa M (1998) Neuromuscular toxicities of paclitaxel 210 mg m(-2) by 3-hour infusion. Br J Cancer 77:1686–1688PubMedPubMedCentralCrossRef
12.
Zurück zum Zitat Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC (1993) Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 20:1–15PubMed Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC (1993) Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 20:1–15PubMed
13.
Zurück zum Zitat Loprinzi CL, Reeves BN, Dakhil SR, Sloan JA, Wolf SL, Burger KN et al (2011) Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1. J Clin Oncol 29:1472–1478PubMedPubMedCentralCrossRef Loprinzi CL, Reeves BN, Dakhil SR, Sloan JA, Wolf SL, Burger KN et al (2011) Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1. J Clin Oncol 29:1472–1478PubMedPubMedCentralCrossRef
14.
Zurück zum Zitat Reeves BN, Dakhil SR, Sloan JA, Wolf SL, Burger KN, Kamal A et al (2012) Further data supporting that paclitaxel-associated acute pain syndrome is associated with development of peripheral neuropathy: North Central Cancer Treatment Group trial N08C1. Cancer 118:5171–5178PubMedCrossRef Reeves BN, Dakhil SR, Sloan JA, Wolf SL, Burger KN, Kamal A et al (2012) Further data supporting that paclitaxel-associated acute pain syndrome is associated with development of peripheral neuropathy: North Central Cancer Treatment Group trial N08C1. Cancer 118:5171–5178PubMedCrossRef
15.
Zurück zum Zitat Asthana R, Zhang L, Wan BA, Gallo-Hershberg D, Giotis A, Pasetka M et al (2020) Pain descriptors of taxane acute pain syndrome (TAPS) in breast cancer patients-a prospective clinical study. Support Care Cancer 28:589–598PubMedCrossRef Asthana R, Zhang L, Wan BA, Gallo-Hershberg D, Giotis A, Pasetka M et al (2020) Pain descriptors of taxane acute pain syndrome (TAPS) in breast cancer patients-a prospective clinical study. Support Care Cancer 28:589–598PubMedCrossRef
17.
Zurück zum Zitat Ueda H (2006) Molecular mechanisms of neuropathic painphenotypic switch and initiation mechanisms. Pharmacol Ther 109:57–77PubMedCrossRef Ueda H (2006) Molecular mechanisms of neuropathic painphenotypic switch and initiation mechanisms. Pharmacol Ther 109:57–77PubMedCrossRef
18.
Zurück zum Zitat Kanbayashi Y, Sakaguchi K, Nakatsukasa K, Ouchi Y, Tabuchi Y, Yoshioka T et al (2019) Predictive factors for taxane acute pain syndrome determined by ordered logistic regression analysis. Support Care Cancer 27:2673–2677PubMedCrossRef Kanbayashi Y, Sakaguchi K, Nakatsukasa K, Ouchi Y, Tabuchi Y, Yoshioka T et al (2019) Predictive factors for taxane acute pain syndrome determined by ordered logistic regression analysis. Support Care Cancer 27:2673–2677PubMedCrossRef
19.
Zurück zum Zitat Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J (1999) Use of low-dose oral prednisone to prevent paclitaxel-induced arthralgias and myalgias. Gynecol Oncol 72:100–101PubMedCrossRef Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J (1999) Use of low-dose oral prednisone to prevent paclitaxel-induced arthralgias and myalgias. Gynecol Oncol 72:100–101PubMedCrossRef
20.
Zurück zum Zitat Yoshida T, Sawa T, Ishiguro T, Horiba A, Minatoguchi S, Fujiwara H (2009) The efficacy of prophylactic Shakuyaku-Kanzo-to for myalgia and arthralgia following carboplatin and paclitaxel combination chemotherapy for non-small cell lung cancer. Support Care Cancer 17:315–320PubMedCrossRef Yoshida T, Sawa T, Ishiguro T, Horiba A, Minatoguchi S, Fujiwara H (2009) The efficacy of prophylactic Shakuyaku-Kanzo-to for myalgia and arthralgia following carboplatin and paclitaxel combination chemotherapy for non-small cell lung cancer. Support Care Cancer 17:315–320PubMedCrossRef
21.
Zurück zum Zitat Nguyen VH, Lawrence HJ (2004) Use of gabapentin in the prevention of taxane-induced arthralgias and myalgias. J Clin Oncol 22:1767–1769PubMedCrossRef Nguyen VH, Lawrence HJ (2004) Use of gabapentin in the prevention of taxane-induced arthralgias and myalgias. J Clin Oncol 22:1767–1769PubMedCrossRef
22.
Zurück zum Zitat Chiu N, Chiu L, Chow R, Lam H, Verma S, Pasetka M et al (2017) Taxane-induced arthralgia and myalgia: a literature review. J Oncol Pharm Pract 23:56–67PubMedCrossRef Chiu N, Chiu L, Chow R, Lam H, Verma S, Pasetka M et al (2017) Taxane-induced arthralgia and myalgia: a literature review. J Oncol Pharm Pract 23:56–67PubMedCrossRef
23.
Zurück zum Zitat Jacobson SD, Loprinzi CL, Sloan JA, Wilke JL, Novotny PJ, Okuno SH et al (2003) Glutamine does not prevent paclitaxel-associated myalgias and arthralgias. J Support Oncol 1:274–278PubMed Jacobson SD, Loprinzi CL, Sloan JA, Wilke JL, Novotny PJ, Okuno SH et al (2003) Glutamine does not prevent paclitaxel-associated myalgias and arthralgias. J Support Oncol 1:274–278PubMed
24.
Zurück zum Zitat Vogel CL, Wojtukiewicz MZ, Carroll RR, Tjulandin SA, Barajas-Figueroa LJ, Wiens BL et al (2005) First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 23:1178–1184PubMedCrossRef Vogel CL, Wojtukiewicz MZ, Carroll RR, Tjulandin SA, Barajas-Figueroa LJ, Wiens BL et al (2005) First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 23:1178–1184PubMedCrossRef
25.
Zurück zum Zitat Balducci L, Al-Halawani H, Charu V, Tam J, Shahin S, Dreiling L et al (2007) Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim. Oncologist 12:1416–1424PubMedCrossRef Balducci L, Al-Halawani H, Charu V, Tam J, Shahin S, Dreiling L et al (2007) Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim. Oncologist 12:1416–1424PubMedCrossRef
26.
Zurück zum Zitat Pinto L, Liu Z, Doan Q, Bernal M, Dubois R, Lyman G (2007) Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials. Curr Med Res Opin 23:2283–2295PubMedCrossRef Pinto L, Liu Z, Doan Q, Bernal M, Dubois R, Lyman G (2007) Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials. Curr Med Res Opin 23:2283–2295PubMedCrossRef
27.
Zurück zum Zitat Cooper KL, Madan J, Whyte S, Stevenson MD, Akehurst RL (2011) Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer 11:404PubMedPubMedCentralCrossRef Cooper KL, Madan J, Whyte S, Stevenson MD, Akehurst RL (2011) Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer 11:404PubMedPubMedCentralCrossRef
28.
Zurück zum Zitat Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ et al (2015) Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 33:3199–3212PubMedCrossRef Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ et al (2015) Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 33:3199–3212PubMedCrossRef
29.
Zurück zum Zitat Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T et al (2008) Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358:1663–1671PubMedPubMedCentralCrossRef Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T et al (2008) Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358:1663–1671PubMedPubMedCentralCrossRef
30.
Zurück zum Zitat Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ et al (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:1431–1439PubMedCrossRef Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ et al (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:1431–1439PubMedCrossRef
31.
Zurück zum Zitat Jones SE, Savin MA, Holmes FA, O’Shaughnessy JA, Blum JL, Vukelja S et al (2006) Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 24:5381–5387PubMedCrossRef Jones SE, Savin MA, Holmes FA, O’Shaughnessy JA, Blum JL, Vukelja S et al (2006) Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 24:5381–5387PubMedCrossRef
32.
Zurück zum Zitat Lambertini M, Del Mastro L, Bellodi A, Pronzato P (2014) The five “Ws” for bone pain due to the administration of granulocyte-colony stimulating factors (G-CSFs). Crit Rev Oncol Hematol 89:112–128PubMedCrossRef Lambertini M, Del Mastro L, Bellodi A, Pronzato P (2014) The five “Ws” for bone pain due to the administration of granulocyte-colony stimulating factors (G-CSFs). Crit Rev Oncol Hematol 89:112–128PubMedCrossRef
33.
Zurück zum Zitat Moore DC, Pellegrino AE (2017) Pegfilgrastim-induced bone pain: a review on incidence, risk factors, and evidence-based management. Ann Pharmacother 51:797–803PubMedCrossRef Moore DC, Pellegrino AE (2017) Pegfilgrastim-induced bone pain: a review on incidence, risk factors, and evidence-based management. Ann Pharmacother 51:797–803PubMedCrossRef
34.
Zurück zum Zitat Kosaka Y, Rai Y, Masuda N, Takano T, Saeki T, Nakamura S et al (2015) Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy. Support Care Cancer 23:1137–4311PubMedPubMedCentralCrossRef Kosaka Y, Rai Y, Masuda N, Takano T, Saeki T, Nakamura S et al (2015) Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy. Support Care Cancer 23:1137–4311PubMedPubMedCentralCrossRef
35.
Zurück zum Zitat Gregory SA, Schwartzberg LS, Mo M, Sierra J, Vogel C (2010) Evaluation of reported bone pain in cancer patients receiving chemotherapy in pegfilgrastim clinical trials: a retrospective analysis. Comm Oncol 7:297–308CrossRef Gregory SA, Schwartzberg LS, Mo M, Sierra J, Vogel C (2010) Evaluation of reported bone pain in cancer patients receiving chemotherapy in pegfilgrastim clinical trials: a retrospective analysis. Comm Oncol 7:297–308CrossRef
36.
Zurück zum Zitat Xu H, Gong Q, Vogl FD, Reiner M, Page JH (2016) Risk factors for bone pain among patients with cancer receiving myelosuppressive chemotherapy and pegfilgrastim. Support Care Cancer 24:723–730PubMedCrossRef Xu H, Gong Q, Vogl FD, Reiner M, Page JH (2016) Risk factors for bone pain among patients with cancer receiving myelosuppressive chemotherapy and pegfilgrastim. Support Care Cancer 24:723–730PubMedCrossRef
37.
Zurück zum Zitat Moukharskaya J, Abrams DM, Ashikaga T, Khan F, Schwartz J, Wilson K et al (2016) Randomized phase II study of loratadine for the prevention of bone pain caused by pegfilgrastim. Support Care Cancer 24:3085–3093PubMedPubMedCentralCrossRef Moukharskaya J, Abrams DM, Ashikaga T, Khan F, Schwartz J, Wilson K et al (2016) Randomized phase II study of loratadine for the prevention of bone pain caused by pegfilgrastim. Support Care Cancer 24:3085–3093PubMedPubMedCentralCrossRef
38.
Zurück zum Zitat Gavioli E, Abrams M (2017) Prevention of granulocyte-colony stimulating factor (G-CSF) induced bone pain using double histamine blockade. Support Care Cancer 25:817–822PubMedCrossRef Gavioli E, Abrams M (2017) Prevention of granulocyte-colony stimulating factor (G-CSF) induced bone pain using double histamine blockade. Support Care Cancer 25:817–822PubMedCrossRef
40.
Zurück zum Zitat Kirshner JJ, Heckler CE, Janelsins MC, Dakhil SR, Hopkins JO, Coles C et al (2012) Prevention of pegfilgrastim-induced bone pain: a phase III double-blind placebo-controlled randomized clinical trial of the university of rochester cancer center clinical community oncology program research base. J Clin Oncol 30:1974–1979PubMedPubMedCentralCrossRef Kirshner JJ, Heckler CE, Janelsins MC, Dakhil SR, Hopkins JO, Coles C et al (2012) Prevention of pegfilgrastim-induced bone pain: a phase III double-blind placebo-controlled randomized clinical trial of the university of rochester cancer center clinical community oncology program research base. J Clin Oncol 30:1974–1979PubMedPubMedCentralCrossRef
41.
Zurück zum Zitat Gibson SJ, Helme RD (2001) Age-related differences in pain perception and report. Clin Geriatr Med 17:433–456PubMedCrossRef Gibson SJ, Helme RD (2001) Age-related differences in pain perception and report. Clin Geriatr Med 17:433–456PubMedCrossRef
42.
Zurück zum Zitat Tamura K, Aiba K, Saeki T, Nakanishi Y, Kamura T, Baba H et al (2015) Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan. Int J Clin Oncol 20:855–865PubMedCrossRef Tamura K, Aiba K, Saeki T, Nakanishi Y, Kamura T, Baba H et al (2015) Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan. Int J Clin Oncol 20:855–865PubMedCrossRef
43.
Zurück zum Zitat Majem M, Moreno ME, Calvo N, Feliu A, Pérez J, Mangues MA (2011) Perception of healthcare providers versus patient reported incidence of chemotherapy-induced nausea and vomiting after the addition of NK-1 receptor antagonists. Support Care Cancer 19:1983–1990PubMedCrossRef Majem M, Moreno ME, Calvo N, Feliu A, Pérez J, Mangues MA (2011) Perception of healthcare providers versus patient reported incidence of chemotherapy-induced nausea and vomiting after the addition of NK-1 receptor antagonists. Support Care Cancer 19:1983–1990PubMedCrossRef
Metadaten
Titel
Risk factor analysis for taxane-associated acute pain syndrome under the dexamethasone prophylaxis
verfasst von
Yoshitaka Saito
Yoh Takekuma
Masaki Kobayashi
Tatsuhiko Sakamoto
Hiroko Yamashita
Mitsuru Sugawara
Publikationsdatum
06.07.2021
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 12/2021
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-021-06342-2

Weitere Artikel der Ausgabe 12/2021

Supportive Care in Cancer 12/2021 Zur Ausgabe

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

12.05.2024 Prostatakarzinom Nachrichten

Ein hoher Anteil pflanzlicher Nahrung trägt möglicherweise dazu bei, das Progressionsrisiko von Männern mit Prostatakarzinomen zu senken. In einer US-Studie war das Risiko bei ausgeprägter pflanzlicher Ernährung in etwa halbiert.

Alter verschlechtert Prognose bei Endometriumkarzinom

11.05.2024 Endometriumkarzinom Nachrichten

Ein höheres Alter bei der Diagnose eines Endometriumkarzinoms ist mit aggressiveren Tumorcharakteristika assoziiert, scheint aber auch unabhängig von bekannten Risikofaktoren die Prognose der Erkrankung zu verschlimmern.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.